Table 3.
All patients with AHF (n=507) |
Group 1 (n=335) |
Group 2 (n=172) |
P value | |
Biological analysis | ||||
Performed | 507 (100%) | 335 (100%) | 172 (100%) | |
Sodium, mmol/L | 138 (135; 141) | 138 (135; 141) | 139 (135; 141) | 0.40 |
Potassium, mmol/L | 4 (4, 5) | 4 (4, 5) | 4 (4, 5) | 0.89 |
Creatinine clearance, mL/min | 50 (35; 69.05) | 40 (29; 49.9) | 78.5 (67; 91) | <0.01 |
Creatinine clearance <30 mL/min | 89 (17.55%) | 89 (26.57%) | 0 (0%) | <0.01 |
Haemoglobin, g/L | 130 (110, 140) | 120 (110, 130) | 130 (130, 140) | 0.06 |
Troponin positive | 271 (53.45%) | 195 (58.21%) | 76 (44.19%) | <0.01 |
BNP, ng/L | 991 (507.5; 2443.5) | 1157.5 (569.25; 2680.5) | 534 (291; 1292) | <0.01 |
Pro-BNP, ng/L | 4025 (1729; 8863) | 5120 (2520; 12 399.75) | 2513 (1146.5; 5376.5) | <0.01 |
ECG | ||||
Performed | 500 (98.61%) | 329 (98.20%) | 171 (99.41%) | |
Sinusal | 220 (44%) | 145 (43.28%) | 75 (43.6%) | 0.92 |
Atrial fibrillation | 213 (42.01) | 139 (41.49%) | 74 (43.02%) | 1.00 |
Driven | 44 (8.8%) | 33 (9.85%) | 11 (6.4%) | 0.19 |
AVB | 21 (4.14%) | 14 (4.18%) | 7 (4.07%) | 0.86 |
LBBB | 86 (17.2%) | 64 (19.1%) | 22 (12.79%) | <0.05 |
RBBB | 59 (11.8%) | 34 (10.15%) | 25 (14.53%) | 0.43 |
Repolarisation disorder | 101 (20.2%) | 73 (21.79%) | 28 (16.28%) | 0.09 |
Chest X-ray | ||||
Performed | 481 (94.87%) | 318 (94.92%) | 163 (94.76%) | |
Normal | 24 (4.73%) | 11 (3.28%) | 13 (7.56%) | 0.20 |
Cardiomegaly | 235 (48.86%) | 171 (51.04%) | 64 (37.21%) | 0.01 |
Interstitial opacities | 284 (59.04%) | 202 (60.3%) | 82 (47.67%) | 0.02 |
Alveolar opacities | 108 (22.45%) | 64 (19.1%) | 44 (25.58%) | 0.05 |
Data are median (IQR) mmol/L, median (IQR) mL/min, median (IQR) g/dL, median (IQR) ng/L or number (%) of patients.
Group 1: patients with CRS; group 2: patients with normal renal function.
AHF, acute heart failure; AVB, atrioventricular block; BNP, brain natriuretic peptide; CRS, cardiorenal syndrome; LBBB, left bundle branch block; RBBB, right bundle branch block.